<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR1800016458</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2018-06-02</date_registration>
      <primary_sponsor>Peking University People's Hospital &amp; Peking University Institute of Hematology</primary_sponsor>
      <public_title>Minimal residual disease assessed by multi-parameter flow cytometry for leukemia stem cells in patients with acute myeloid leukaemia who underwent allogeneic stem cell transplantation</public_title>
      <acronym />
      <scientific_title>Minimal residual disease assessed by multi-parameter flow cytometry for leukemia stem cells in patients with acute myeloid leukaemia who underwent allogeneic stem cell transplantation</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2018-06-30</date_enrolment>
      <type_enrolment />
      <target_size>Case series:360;</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=27944</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>Other</phase>
      <hc_freetext>Acute leukemia</hc_freetext>
      <i_freetext>Case series:Post allogeneic stem cell transplantation;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Chang Yingjun</firstname>
        <middlename />
        <lastname />
        <address>11 Xizhimen Street South, Xicheng District, Beijing, China</address>
        <city />
        <country1 />
        <zip>100044</zip>
        <telephone>+86 13520536738</telephone>
        <email>rmcyj@bjmu.edu.cn</email>
        <affiliation>Peking University People's Hospital &amp; Peking University Institute of Hematology</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Chang Yingjun</firstname>
        <middlename />
        <lastname />
        <address>11 Xizhimen Street South, Xicheng District, Beijing, China</address>
        <city />
        <country1 />
        <zip>100044</zip>
        <telephone>+86 13520536738</telephone>
        <email>rmcyj@bjmu.edu.cn</email>
        <affiliation>Peking University People's Hospital &amp; Peking University Institute of Hematology</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1) Allogeneic stem cell transplantation candidates with acute myeloid leukemia. Donor selection was performed as the follows: HLA-matched sibling donor was the first choice for allo-transplantation. If an HLA-matched sibling donor was unavailable, subjects without a suitable closely HLA-matched unrelated donor (URD; &gt;8 of 10 matching HLA-A, B, C, DR, and DQloci and &gt;5 of 6 matching HLA-A, B, and DR loci) after 2 cycles of consolidation were eligible for HLA-haplotype transplantation;
2) Between 6 and 60 years-old; 
3) To be able to provide written informed consent.</inclusion_criteria>
      <agemin>6</agemin>
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1) Contraindications of transplantation; 
2) Subjects who cannot comply with the study.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Relapse;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>the National Key Research and Development Program of China</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-07-25</approval_date>
        <contact_name>Liu Kaiyan</contact_name>
        <contact_address>Peking University People's Hospital, 11 Xizhimen Street South, Xicheng District, Beijing, China</contact_address>
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>